Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344487 · ClinicalTrials.gov registry record · NA
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
A NA study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00344487 is a NA study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 3 participants.
The verdict
NCT00344487, a NA study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
To explore the hypothesis that the use of Lopinavir/ritonavir will be associated with improved CD4 immune reconstitution in volunteers who fail to demonstrate a significant CD4 cell increase (while on their first antiretroviral treatment regimen) despite sustained viral suppression by a non-Lopinavir/ritonavir-containing regimen
Interventions
- DRUG Lopinavir/Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344487
The ClinicalTrials.gov registry entry for NCT00344487 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lopinavir/Ritonavir is the first listed.
NCT00344487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00344487 about?
NCT00344487 is a clinical study titled "Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study". To explore the hypothesis that the use of Lopinavir/ritonavir will be associated with improved CD4 immune reconstitution in volunteers who fail to demonstrate a significant CD4 cell increase (while on their first antiretroviral treatment regimen) despite sustained viral suppression by a non-Lopinavi...
What is the current status of trial NCT00344487?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2005-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00344487?
The interventions under investigation include: Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00344487?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.